Tesamorelin vs CJC-1295 for research: which to pick
A buyer's comparison of tesamorelin, CJC-1295 and the ipamorelin pairing, covering what each compound is, how the two published records differ in size and type, and which batch documents to check before ordering.
Answering cjc 1295 ipamorelin vs tesamorelin means separating three compounds that the phrase runs together. Tesamorelin and CJC-1295 are both analogues of growth hormone-releasing hormone (GHRH) acting at the GHRH receptor, while ipamorelin acts at the ghrelin receptor GHS-R1a, so the decision is between one GHRH analogue with a large clinical record and a two-receptor pairing whose human data are far thinner.
This article is written for laboratory researchers and buyers choosing between two catalogue entries rather than between two versions of one molecule. The listings compared here are Tesamorelin 10mg, a 44-amino-acid GHRH analogue, and CJC-1295 no DAC 10mg, the shorter GHRH(1-29) analogue that carries no albumin-binding linker. Both are supplied as lyophilised powder for laboratory research, and each product page carries one Certificate, a report from a named laboratory outside AKH ordered by the manufacturer.
Key takeaways
- Tesamorelin and CJC-1295 are both GHRH receptor analogues; ipamorelin is a ghrelin-receptor agonist, so the pairing spans two receptor classes.
- The tesamorelin evidence record cites 15 published studies, 11 of them since 2023, concentrated in HIV-associated lipodystrophy and hepatic fat.
- The CJC-1295 record cites 16 studies, but its human data are small phase I and phase II studies of the DAC form, and no randomised controlled trial of the no-DAC form was located.
- A 2026 review covering all three compounds describes preclinical work as promising and states that clinical trials are currently lacking.
- Published batches: tesamorelin batch 26094 at 99.66% on 14 Aug 2026, and CJC-1295 no DAC batch 26082 at 99.94% on 02 Aug 2026, both tested by the Brown Institute of Biomolecular Research.
What tesamorelin, CJC-1295 and ipamorelin each are
Tesamorelin, also written TH9507, is a synthetic analogue of human GHRH built on the full 44-amino-acid sequence. The product page states that a trans-3-hexenoyl group attached to the tyrosine at position 1 confers resistance to cleavage by dipeptidyl peptidase-IV, and the tesamorelin evidence record describes the compound as acting at the GHRH receptor on pituitary somatotroph cells.
CJC-1295 is a family name for two related GHRH receptor agonists derived from the N-terminal 29-amino-acid fragment of human GHRH. The DAC form carries a maleimidopropionyl linker that forms a covalent complex with circulating albumin and extends the reported plasma half-life to roughly one to two weeks; the no-DAC form, more accurately termed modified GRF(1-29), lacks that linker and has a short duration of action comparable to sermorelin.
Ipamorelin is the third name in the search phrase and belongs to a different class. It is a ghrelin-mimetic acting at the GH secretagogue receptor GHS-R1a. Because the GHRH and ghrelin-receptor pathways are separate, the CJC-1295 product page notes that GHRH analogues are commonly co-studied with GHS-R1a agonists such as ipamorelin, which is how the two names end up joined in a single query.
| Feature | Tesamorelin | CJC-1295 no DAC |
|---|---|---|
| Receptor | GHRH receptor | GHRH receptor |
| Construct | 44-amino-acid GHRH analogue with a hexenoyl group at the N-terminus | GHRH(1-29) fragment with four substitutions and no albumin-binding linker |
| Studies cited in the evidence record | 15, of which 11 published since 2023 | 16, of which 8 published since 2023 |
| Human trial position in that record | Phase 3 programmes in HIV-associated lipodystrophy, plus investigator-initiated trials in hepatic fat and cognition | Small phase I and phase II studies of the DAC form, 2005 to 2009; no randomised controlled trial of the no-DAC form located |
| Regulatory position | Approved medicine for HIV-associated lipodystrophy (FDA approval November 2010, brand Egrifta); the catalogue material is a research compound | No marketing authorisation in any jurisdiction; appears on the World Anti-Doping Agency Prohibited List |
| Published batch in the catalogue | Batch 26094, tested 14 Aug 2026, 99.66% | Batch 26082, tested 02 Aug 2026, 99.94% |
How the two published records differ in size and type
The two records are close in total size and far apart in composition. The tesamorelin record cites 15 published studies, 11 of them since 2023, and its centre of gravity is the phase 3 programme in HIV-associated lipodystrophy, where visceral adipose tissue was the primary endpoint. Later investigator-initiated work extended to hepatic fat in NAFLD and MASLD, to neurocognitive endpoints, and to lean mass and physical function.
The CJC-1295 record cites 16 studies, 8 of them since 2023, but it states that human data are confined to a small number of phase I and phase II studies of the DAC form conducted between 2005 and 2009. No peer-reviewed randomised controlled trial of the non-DAC form was located, and most literature published since 2019 concerns anti-doping detection methodology or narrative reviews rather than new clinical data.
Both records state their limits plainly. For tesamorelin, controlled evidence outside HIV-associated visceral adiposity and hepatic steatosis remains limited, cognitive trials have been small and inconsistent, and no long-term cardiovascular or oncological outcome data have been established. For CJC-1295, long-term safety, body composition, glucose tolerance during sustained IGF-1 elevation and any clinical outcome endpoint remain unestablished for both forms.
A 2026 review in the orthopaedic literature (Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions) groups ipamorelin, CJC-1295 and tesamorelin among growth hormone secretagogues acting through IGF-1 signalling, and states that preclinical studies are promising while clinical trials are currently lacking. That is the level at which the three names are covered together in the supplied literature: a narrative review, not a head-to-head study.
The cjc 1295 ipamorelin vs tesamorelin decision: how to choose a research question
The choice is usually settled by the design rather than by the compound's reputation. Four checks do most of the work, and three of them are about the literature rather than the vial.
- 01
Name the receptor question first
A design that examines GHRH-receptor signalling alone needs one GHRH analogue. A design that examines two receptor classes needs the ipamorelin pairing, because ipamorelin acts at GHS-R1a rather than at the GHRH receptor.
- 02
Match the form to the literature
Human CJC-1295 data belong to the DAC form, while the catalogue entry is the no-DAC form and the record locates no randomised controlled trial of it. Tesamorelin's record, by contrast, is dominated by the full-length analogue that the trials actually used.
- 03
Check the evidence tier, not the study count
The two totals are similar, but tesamorelin's includes phase 3 programmes and meta-analyses of randomised trials, while CJC-1295's includes early-phase work and a large body of analytical chemistry. The 2026 review that covers all three compounds states that clinical trials for the class are currently lacking.
- 04
Decide what documentation settles the order
For either compound, the checkable document is the Certificate on the product page: it should name the material, the batch, the laboratory, the test date and a results line that matches the archive row.
Reading the batch documents for each compound
Both catalogue entries publish one Certificate and both rows appear in the COA archive. The tesamorelin page carries batch 26094, tested 14 Aug 2026 by the Brown Institute of Biomolecular Research, with the results line Tesamorelin: 10mg | Purity: 99.66%. The CJC-1295 page carries batch 26082, tested 02 Aug 2026 by the same laboratory, with the results line CJC 1295 no DAC: 10mg | Purity: 99.94%. The form declaration sits inside that second results line, which matters because the family name alone would not say which of the two CJC-1295 molecules was analysed.
Each Certificate is a test report from a named laboratory outside AKH, ordered by the manufacturer and shown as issued. It documents a measurement for one batch. It is not a manufacturing standard, a sterility statement, or evidence per batch across the catalogue.
Purity is also not quantity. A chromatographic purity figure is a peak-area ratio taken from the chromatogram, and lyophilised peptide is normally supplied as an acetate or trifluoroacetate salt with residual water, so the mass of powder in a vial is not the same quantity as the peptide content. Net peptide content is a separate measurement, and neither results line reports one.
Where to check each listing before ordering
The buying decision follows the research question. For work on GHRH-receptor signalling with the deeper clinical record behind it, the Tesamorelin 10mg page is the place to check the 10mg presentation, its Certificate and the stated shipping terms. For a two-receptor design, the CJC-1295 no DAC 10mg page is the equivalent check, with the form caveat above attached to it.
Both listings state worldwide delivery in a 9 to 14 day window and supply the material as lyophilised powder for laboratory research only. The tesamorelin listing states that it is not for human or veterinary use even though an approved tesamorelin medicine exists, and the CJC-1295 listing carries the same research-use-only framing. A Certificate from a named outside laboratory does not change either position.
The study lists and the stated limits for each compound sit in the research records rather than in this article, and those records are the right place to test whether a proposed design is already covered by published work. The catalogue pages answer the separate question of what is in the vial and which laboratory measured it.
Common questions.
- Which has more published research, tesamorelin or CJC-1295?
The totals are close and the composition is not. The tesamorelin record cites 15 studies, 11 since 2023, built around phase 3 programmes in HIV-associated lipodystrophy and later trials in hepatic fat and cognition. The CJC-1295 record cites 16 studies, 8 since 2023, but states that human data are confined to small phase I and phase II studies of the DAC form conducted between 2005 and 2009.
- Has any single trial compared the CJC-1295 and ipamorelin pair with tesamorelin?
No such study appears in the supplied records. The CJC-1295 record locates no randomised controlled trial of the no-DAC form at all, and the 2026 review that covers ipamorelin, CJC-1295 and tesamorelin states that clinical trials for the class are currently lacking. The available material is component-level rather than comparative.
- What does ipamorelin contribute to a CJC-1295 research design?
A second receptor target. CJC-1295 acts at the GHRH receptor and ipamorelin at the ghrelin receptor GHS-R1a, so a design that includes both examines two pathways rather than one. The CJC-1295 product page attributes the common pairing to the fact that the two pathways are separate.
- Does the regulatory status of tesamorelin and CJC-1295 differ?
Yes. Tesamorelin is an approved medicine for HIV-associated lipodystrophy, with FDA approval in November 2010 under the brand Egrifta. The CJC-1295 record states that the compound holds no marketing authorisation in any jurisdiction and appears on the World Anti-Doping Agency Prohibited List. Both catalogue entries are supplied for laboratory research only.
Sources
- 01COA archive — every published Certificate · AKH BioLabs
- 02Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
- 03Buy Tesamorelin 10mg: COA & Research Supply · AKH BioLabs
- 04Tesamorelin research — published studies and evidence · AKH BioLabs
- 05Buy CJC-1295 No DAC 10mg: Batch COA · AKH BioLabs
- 06CJC-1295 research — published studies and evidence · AKH BioLabs